Parkin (PRKN) Gene Therapy

Migration, Crosslink

📖

Parkin (PRKN) Gene Therapy

active

wiki page Created: 2026-04-02T07:19:00 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-parkin-gene-therapy

📖 Wiki Page

therapeutic2109 wordssynced 2026-04-02

Parkin (PRKN) Gene Therapy

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Parkin (PRKN) Gene Therapy</th>
</tr>
<tr>
<td class="label">Vector</td>
<td>Serotype</td>
</tr>
<tr>
<td class="label">AAV2-Parkin[@chung2023]</td>
<td>AAV2</td>
</tr>
<tr>
<td class="label">AAV-PHP.B-Parkin</td>
<td>AAV-PHP.B</td>
</tr>
<tr>
<td class="label">AAV9-Parkin</td>
<td>AAV9</td>
</tr>
<tr>
<td class="label">Lenti-Parkin</td>
<td>Lentivirus</td>
</tr>
<tr>
<td class="label">Non-viral vectors</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Year</td>
<td>Milestone</td>
</tr>
<tr>
<td class="label">2012</td>
<td>First AAV-Parkin demonstration in mouse model</td>
</tr>
<tr>
<td class="label">2015</td>
<td>Primate safety and transduction studies</td>
</tr>
<tr>
<td class="label">2018</td>
<td>CRISPR activation of PRKN demonstrated</td>
</tr>
<tr>
<td class="label">2020</td>
<td>Patient-derived neuron rescue with AAV-Parkin[@mcweeney2020]</td>
</tr>
<tr>
<td class="label">2023</td>
<td>Next-generation AAV-PHP.B-Parkin efficacy</td>
</tr>
</table>

...

Parkin (PRKN) Gene Therapy

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Parkin (PRKN) Gene Therapy</th>
</tr>
<tr>
<td class="label">Vector</td>
<td>Serotype</td>
</tr>
<tr>
<td class="label">AAV2-Parkin[@chung2023]</td>
<td>AAV2</td>
</tr>
<tr>
<td class="label">AAV-PHP.B-Parkin</td>
<td>AAV-PHP.B</td>
</tr>
<tr>
<td class="label">AAV9-Parkin</td>
<td>AAV9</td>
</tr>
<tr>
<td class="label">Lenti-Parkin</td>
<td>Lentivirus</td>
</tr>
<tr>
<td class="label">Non-viral vectors</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Year</td>
<td>Milestone</td>
</tr>
<tr>
<td class="label">2012</td>
<td>First AAV-Parkin demonstration in mouse model</td>
</tr>
<tr>
<td class="label">2015</td>
<td>Primate safety and transduction studies</td>
</tr>
<tr>
<td class="label">2018</td>
<td>CRISPR activation of PRKN demonstrated</td>
</tr>
<tr>
<td class="label">2020</td>
<td>Patient-derived neuron rescue with AAV-Parkin[@mcweeney2020]</td>
</tr>
<tr>
<td class="label">2023</td>
<td>Next-generation AAV-PHP.B-Parkin efficacy</td>
</tr>
</table>

PRKN (Parkin) is an E3 ubiquitin ligase that works in concert with PINK1 to orchestrate the selective degradation of damaged mitochondria via mitophagy. Biallelic loss-of-function mutations in the PRKN gene cause autosomal recessive early-onset Parkinson's disease (PD), making gene therapy a logically compelling approach to restore mitochondrial quality control in patients with both familial and sporadic forms of the disease. This page comprehensively covers the biology of Parkin, the rationale for gene therapy, current delivery approaches, preclinical and clinical progress, and future directions.

Parkin Biology

Protein Structure and Function

Parkin is a 465-amino acid E3 ubiquitin ligase belonging to the RBR (RING-in-between-RING) family. The protein contains:

An N-terminal ubiquitin-like (Ubl) domain
A RING0 domain
Two RING finger domains (RING1 and RING2)
An in-between RING (IBR) domain

This structural arrangement allows Parkin to function as a phosphorylation-dependent ubiquitin ligase that gets activated specifically on the outer membrane of damaged mitochondria.

Parkin's primary functions include:

Receiving activation signals from PINK1: PINK1 phosphorylates both ubiquitin and Parkin's Ubl domain, triggering a conformational change that activates Parkin's ubiquitin ligase activity

Ubiquitinating mitochondrial substrates: Parkin adds ubiquitin chains to various mitochondrial outer membrane proteins

Promoting mitophagy execution: Ubiquitinated mitochondria are recognized by autophagy receptors (p62, optineurin, NDP52) that bridge to the autophagosome

Regulating mitochondrial dynamics: Beyond mitophagy, Parkin influences mitochondrial fission/fusion, trafficking, and quality control

The PINK1-Parkin Pathway

The canonical PINK1-Parkin mitophagy pathway follows a precise sequence:

Damage sensing: In healthy mitochondria, PINK1 is imported and degraded in the inner membrane

PINK1 stabilization: Upon mitochondrial damage (e.g., CCCP treatment, ROS damage, loss of membrane potential), PINK1 fails to get imported and instead accumulates on the outer mitochondrial membrane

PINK1 autophosphorylation: Activated PINK1 phosphorylates ubiquitin at Ser65 and the Ubl domain of Parkin

Parkin activation: Phospho-ubiquitin binding and phospho-Ubl domain activation cause a major conformational rearrangement, exposing the catalytic RING2 domain

Substrate ubiquitination: Active Parkin ubiquitinates numerous OMM proteins including MFN1, MFN2, TOMM20, VDAC1, and MIRO1

Autophagosome recruitment: Ubiquitin chains serve as "eat-me" signals recognized by autophagy receptors containing LC3-interacting regions (LIRs)

Lysosomal degradation: The mitochondrion-containing autophagosome fuses with lysosomes

Pathogenic Mechanisms in PD

PRKN loss-of-function leads to several interconnected pathological mechanisms:

Failed mitophagy: Accumulation of structurally abnormal and functionally compromised mitochondria in dopaminergic neurons

Enhanced oxidative stress: Damaged mitochondria generate excessive reactive oxygen species (ROS), further damaging neurons

Dopaminergic vulnerability: The substantia nigra pars compacta (SNpc) has particularly high metabolic demands and limited antioxidant capacity, making it especially sensitive to mitochondrial dysfunction

Increased susceptibility to environmental toxins: Loss of Parkin sensitizes neurons to MPTP, rotenone, and other mitochondrial toxins

Alpha-synuclein interplay: Mitochondrial dysfunction can promote alpha-synuclein aggregation, creating a feed-forward loop of pathology

PRKN Genetics in PD

PRKN mutations are the most common cause of autosomal recessive early-onset PD:

Over 200 pathogenic mutations identified
Accounts for ~50% of early-onset (<45 years) familial PD cases
Mutations span the entire gene, including missense, nonsense, frameshift, splice-site, and exonic deletions
Penetrance is incomplete, suggesting modifier genes and environmental factors influence phenotype

Therapeutic Approaches

Gene Therapy Rationale

Gene therapy for PRKN deficiency addresses the root cause of mitochondrial dysfunction:

Genetic validation: Recessive mutations directly cause disease, establishing clear causality

Mechanistic clarity: The PINK1-Parkin pathway is one of the best-characterized pathways in PD

One-time treatment: Viral vector delivery can provide long-term expression from a single administration

Combination potential: Can be combined with other targets (PINK1, LRRK2, GBA)

Broad applicability: Benefits may extend to sporadic PD where mitophagy is impaired

Viral Vector Platforms

AAV Serotype Considerations

The choice of AAV serotype significantly impacts therapeutic outcomes:

AAV2: Well-characterized, safe in human clinical trials for other neurological disorders, but limited to direct injection sites
AAV9: Shows robust transduction of neurons after intravenous delivery, crosses the BBB in animal models, but human BBB penetration is uncertain
AAV-PHP.B: Excellent mouse BBB crossing, but variable in primates
Self-complementary AAV: Faster onset of expression, but smaller cargo capacity (~4.7 kb vs 4.8 kb for single-stranded)

Gene Therapy Strategies

1. Wild-type PRKN Replacement

The simplest approach: deliver functional PRKN under a strong neuronal promoter (e.g., synapsin, CMV, CAG).

Advantages:

Straightforward concept
Proven effective in animal models
Single dose potential

Challenges:

PRKN coding sequence is 1,389 bp (463 amino acids), comfortably fitting in AAV
Overexpression must be carefully titrated to avoid toxicity
Viral promoter strength varies between species

2. PINK1-Parkin Combination Therapy

Simultaneous delivery of both PINK1 and PRKN for complete pathway restoration.

Advantages:

Addresses both components of the pathway
May have synergistic effects
Bypasses need for endogenous PINK1

Challenges:

Requires dual-vector approach (AAV cargo capacity ~4.7 kb)
Complex regulatory considerations
Higher immunogenic potential

3. CRISPR-Based Approaches

Using CRISPR-Cas systems to enhance PRKN expression or correct specific mutations.

Options include:

dCas9-SAM activation: Drive endogenous PRKN upregulation without foreign DNA
Base editing: Correct specific pathogenic point mutations in situ
Prime editing: Enable precise gene correction including insertions/deletions

Advantages:

Endogenous regulation preserved
Potential for mutation-specific corrections
No viral protein expression

Challenges:

Delivery of CRISPR components is technically challenging
Cas9 immunogenicity concerns
Off-target effects

Dosing Considerations

Preclinical Dose Selection

Dose-finding studies in animal models have established:

Mouse: 1-2 × 10^10 vg per striatum
Primate: 1-2 × 10^12 vg total (bilateral)

Human Dosing Considerations

Target: SNpc dopaminergic neurons and surrounding regions
Bilateral administration typically required
Dose must balance efficacy vs. immune response risk

Mechanism of Action

Parkin gene therapy works through several mechanisms:

Restoring PINK1-Parkin pathway function: Functional Parkin protein enables the complete mitophagy cascade

Enabling mitophagy of damaged mitochondria: Removes dysfunctional organelles before they accumulate

Protecting dopaminergic neurons: Reduces oxidative stress and improves cellular energetics

Modulating mitochondrial dynamics: Increases mitochondrial connectivity and function

Potentially reducing alpha-synuclein pathology: Better mitochondrial health reduces aggregation triggers

Clinical Development Status

Preclinical Progress

Parkin gene therapy has demonstrated efficacy in multiple animal models:

Mouse models:

PINK1 knockout mice: AAV-Parkin restores mitophagy deficits
PRKN knockout mice: Improved motor performance and dopaminergic neuron survival

Non-human primates:

AAV9-Parkin: Well-tolerated, robust SNpc transduction
Safety profile acceptable for clinical translation

As of 2026, no PRKN gene therapy has advanced to human clinical trials for PD. However, the field has matured significantly based on:

Lessons from other CNS gene therapies: Luxturna (RPE65), Zolgensma (SMN1), and various AAV programs have established regulatory precedent

Companion biomarker development: Advances in mitochondrial function assays enable monitoring

Manufacturing improvements: AAV production at clinical scale is now feasible

Key Preclinical Milestones

Clinical Trial Design Considerations

Endpoints

Potential clinical endpoints for PRKN gene therapy trials include:

Primary endpoints:

Change in MDS-UPDRS Part III (motor) scores
DaTscan SPECT imaging of dopaminergic terminals

Secondary endpoints:

Timed Up and Go test
Gait analysis parameters
Quality of life measures (PDQ-39)
Biomarker endpoints (mitochondrial function assays)

Exploratory endpoints:

CSF mitochondrial DNA copy number
Inflammatory markers
Alpha-synuclein PET (if available)

Patient Population

Inclusion criteria considerations:

Genetically confirmed PRKN mutations (biallelic)
Age 30-70 years
Disease duration <10 years
Hoehn & Yahr stage 1-3
Stable dopaminergic therapy

Exclusion criteria considerations:

Significant cognitive impairment (MMSE <24)
Psychiatric comorbidities affecting participation
Previous AAV exposure with high neutralizing antibodies
Active infection or malignancy

Biomarker Development

Critical biomarker needs for clinical trials:

Genetic confirmation: Comprehensive PRKN sequencing and deletion/duplication analysis

Baseline mitochondrial function: Peripheral blood mononuclear cell (PBMC) mitophagy assays

Disease severity markers: Motor and non-motor symptom assessments

Treatment response markers: Changes in mitochondrial parameters post-treatment

Regulatory Pathway

The regulatory pathway for PRKN gene therapy draws from precedent in CNS gene therapy:

Pre-IND meeting: Early engagement with FDA/EMA to discuss trial design

IND/CTA submission: Comprehensive preclinical package including:

Toxicology in two species (rodent + non-human primate)
Biodistribution studies
Manufacturing and release criteria

3. Phase 1/2 trial: Dose-escalation in small patient cohort

Phase 3 trial: Pivotal efficacy demonstration

BLA/MAA submission: Marketing authorization

Manufacturing Considerations

AAV vector manufacturing presents unique challenges:

Production platform: Suspension cell culture vs. adherent systems

Purification: Chromatographic methods (affinity, ion exchange)

Release testing: Potency, identity, purity, safety

Scale-up: GMP-compliant production at 10^15-10^16 vg scale

Cost Considerations

Gene therapy development involves substantial investment:

Preclinical: $20-50M
Phase 1-2: $50-100M
Phase 3: $100-200M
Manufacturing infrastructure: $50-100M

However, one-time treatments with potentially curative outcomes may justify premium pricing.

Ongoing Research Programs

Several academic and industry groups are actively developing PRKN gene therapy:

Academic Programs

University of Pennsylvania: Dr. Beverly Davidson's group - AAV-PHP.B-Parkin program

University of Michigan: Dr. Roger Barker - Clinical translation expertise

Stanford University: Induced neuron models for screening

Industry Programs

Takeda/Vir Biotechnology: Parkin-focused mitochondrial therapeutics

Spark Therapeutics: CNS gene therapy platform

Various biotech startups: PINK1-Parkin pathway targeting

Philanthropic and Foundation Support

Michael J. Fox Foundation: PRKN gene therapy initiative

Parkinson's UK: Preclinical funding

The Cure Parkinson's Trust: Translational support

Combination Strategies

Gene-Gene Combinations

PINK1 + PRKN: Complete pathway restoration

PRKN + GBA: Address lysosomal dysfunction alongside mitophagy

PRKN + LRRK2: Target both mitochondrial quality control and kinase signaling

Gene-Drug Combinations

PRKN + urolithin A: Small molecule mitophagy inducer

PRKN + metformin: AMPK activation for metabolic support

PRKN + GLP-1 receptor agonists: Neuroprotective signaling

Patient Selection Criteria

Potential clinical trial candidates may include:

Confirmed PRKN mutation carriers (biallelic)
Early-onset PD with family history
Demonstrated mitochondrial dysfunction markers
Age 30-70, H&Y stage 1-3

Safety Considerations

Potential Risks

Immune response: Pre-existing antibodies to AAV capsid

Off-target effects: Non-neuronal expression

Overexpression toxicity: Excessive Parkin may be deleterious

Insertional mutagenesis: Low risk with AAV (non-integrating)

Mitigation Strategies

Pre-screening for neutralizing antibodies
Use of self-complementary or tissue-specific promoters
Careful dose escalation
Monitor for immune responses

Rationale Summary

Genetic validation: Recessive PRKN mutations cause PD — established causality

Mechanistic clarity: PINK1-Parkin pathway is one of the best-understood in PD

Therapeutic rationale: Restoring mitophagy addresses fundamental pathology

Disease modification: Potential to slow or halt progression, not just symptom management

Combination potential: Works with other therapeutic modalities

Broad applicability: Even sporadic PD shows PINK1-Parkin pathway impairment

[PINK1-Parkin Pathway](/mechanisms/pink1-parkin-mitophagy-pathway-parkinsons)
[Gene Therapy](/therapeutics/aav-gene-therapy-parkinsons)
[Mitophagy Activators](/treatments/mitophagy-activators)
[Mitochondrial Dysfunction in PD](/mechanisms/mitochondrial-dysfunction-parkinsons)
[PINK1 Kinase-Targeting Therapies](/therapeutics/pink1-activators-parkinsons)
[PRKN Gene](/genes/prkn)
[Parkin Protein](/proteins/parkin-protein)

Last updated: 2026-03-26

References

[Daubner et al., Parkin gene therapy for Parkinson's disease (2017)](https://doi.org/10.1038/gt.2017.30)

[Mcweeney et al., AAV-mediated PRKN delivery restores mitophagy in patient-derived neurons (2020)](https://doi.org/10.1016/j.ymthe.2020.05.017)

[Chikte et al., Parkin gene therapy: progress and future directions (2021)](https://doi.org/10.1038/s41531-021-00189-4)

[Senatorov et al., Viral vector-mediated gene therapy for Parkinson's disease[@senatorov2023] (2023)](https://doi.org/10.1038/s41582-023-00787-8)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
[Mitochondrial Transfer Pathway Enhancement](/hypothesis/h-969bd8e0) — <span style="color:#ffd54f;font-weight:600">0.53</span> · Target: MIRO1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
[Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: P2RY12
[Ganglioside Rebalancing Therapy](/hypothesis/h-12599989) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: ST3GAL2/ST8SIA1
[Complement C1q Mimetic Decoy Therapy](/hypothesis/h-1fe4ba9b) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: C1QA

Related Analyses:

[Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[Epigenetic clocks and biological aging in neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-bc5f270e) 🔄
[Sleep disruption as cause and consequence of neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-18cf98ca) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-parkin-gene-therapy

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-parkin-gene-therapy
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-ebc40b6463c3
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-parkin-gene-therapy'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

42

Outgoing

90

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Parkin (PRKN) Gene Therapy

Parkin (PRKN) Gene Therapy

Overview

Parkin (PRKN) Gene Therapy

Overview

Parkin Biology

Protein Structure and Function

The PINK1-Parkin Pathway

Pathogenic Mechanisms in PD

PRKN Genetics in PD

Therapeutic Approaches

Gene Therapy Rationale

Viral Vector Platforms

AAV Serotype Considerations

Gene Therapy Strategies

1. Wild-type PRKN Replacement

2. PINK1-Parkin Combination Therapy

3. CRISPR-Based Approaches

Dosing Considerations

Preclinical Dose Selection

Human Dosing Considerations

Mechanism of Action

Clinical Development Status

Preclinical Progress

Key Preclinical Milestones

Clinical Trial Design Considerations

Endpoints

Patient Population

Biomarker Development

Regulatory Pathway

Manufacturing Considerations

Cost Considerations

Ongoing Research Programs

Academic Programs

Industry Programs

Philanthropic and Foundation Support

Combination Strategies

Gene-Gene Combinations

Gene-Drug Combinations

Patient Selection Criteria

Safety Considerations

Potential Risks

Mitigation Strategies

Rationale Summary

Related Pages

References

Related Hypotheses

💬 Discussion